ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Lyka Labs's annualized net income for the quarter that ended in Mar. 2026 was ₹-304 Mil. Lyka Labs's average Total Stockholders Equity over the quarter that ended in Mar. 2026 was ₹924 Mil. Therefore, Lyka Labs's annualized ROE % for the quarter that ended in Mar. 2026 was -32.93%.
The historical rank and industry rank for Lyka Labs's ROE % or its related term are showing as below:
BOM:500259'
s ROE % Range Over the Past 10 Years
Min: -422.31 Med: -12.86 Max: 9.33
Current: -10.13
During the past 13 years, Lyka Labs's highest ROE % was 9.33%. The lowest was -422.31%. And the median was -12.86%.
BOM:500259's ROE % is ranked better than 69.68% of 1250
companies
in the Biotechnology industry
Industry Median: -38.53
vs BOM:500259: -10.13
Lyka Labs (BOM:500259) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Lyka Labs ROE % Related Terms
Lyka Labs ROE % Historical Data
* Premium members only.
The historical data trend for Lyka Labs's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Lyka Labs's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lyka Labs ROE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lyka Labs's ROE % distribution charts can be found below:
* The bar in red indicates where Lyka Labs's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Lyka Labs (BOM:500259) has a ROE % of -32.93% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Lyka Labs and its competitors. According to the industry distribution chart, Lyka Labs ranks #379 out of 1250 companies in the Biotechnology industry, placing it in the top 30.3%.
Is Lyka Labs' ROE % too high?
Lyka Labs' current ROE % is -32.93%. Based on the distribution chart, Lyka Labs ranks #379 out of 1250 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Lyka Labs has a GF Score™ of 60/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lyka Labs' ROE % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Lyka Labs ranks #379 out of 1250 companies for ROE %. This puts Lyka Labs in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Biotechnology company?
A good ROE % depends on the Biotechnology industry context. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Lyka Labs and its competitors. Lyka Labs's current ROE % is -32.93%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lyka Labs stock overvalued right now?
Based on GuruFocus' analysis, Lyka Labs (BOM:500259) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹127.26, compared to a current price of ₹72.36 — trading 43.1% below its estimated fair value. The current ROE % is -32.93%. Lyka Labs' overall GF Score™ is 60/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Lyka Labs (BOM:500259), the current ROE % is -32.93% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lyka Labs (BOM:500259) Overvalued in 2026?
Based on GuruFocus' analysis, Lyka Labs stock appears to be undervalued.
The current stock price of ₹72.36 is trading 43.1% below its estimated GF Value™ of ₹127.26.
GuruFocus considers Lyka Labs to be Significantly Undervalued.
Key valuation signals for BOM:500259:
ROE %: -32.93%
GF Value™: ₹127.26 vs. price of ₹72.36 (43.1% below fair value)
No single metric tells the full story. See the BOM:500259 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lyka Labs Ltd is an Indian biotechnology company. It mainly engages in the development of specialized formulations. The Company is engaged in only one segment which is pharmaceuticals. The Company has a presence in Domestic as well as International markets. The commercialized formulations of the company consist of hair care, anti-aging, acne management, skin lightening, face washes, sunscreens, facial scrubs, and others. It has developed a varied drug delivery system for topical steroids, painkillers, anti-fungal, and other emollients as well as liquid injectables, lyophilized injectables in the anti-bacterial, antifungal segment. The company also manufactures proton pump inhibitors, antibiotics, antifungals, steroids, etc. The majority of the company's revenue comes from India.
60GF Score
Get the complete analysis for BOM:500259
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:500259 has been successfully added to your 
